Stellest lenses, reviewed: what the evidence actually shows

Stellest is Essilor’s myopia control spectacle lens for children. The lens carries a clear central zone with 1,021 tiny lenslets arranged in 11 concentric rings around it, a design Essilor calls H.A.L.T. technology. The lenslets create a volume of myopic defocus in front of the retina, and the working theory is that this optical signal slows the eye’s axial growth. In September 2025 it became the first spectacle lens with FDA market authorization for slowing myopia progression in children, covering ages 6 to 12, and it is sold in the US through LensCrafters and Target Optical. It was already on sale in the UK, Australia, Canada and much of Asia before that.

Almost everything written about Stellest online is published by Essilor, by retailers selling it, or by optometry practices fitting it. This page is none of those. EndMyopia sells nothing lens shaped and has no relationship with any lens maker.

Do Stellest lenses work?

The trial evidence is real and worth stating plainly. The two year randomized controlled trial, run with Wenzhou Medical University and published in JAMA Ophthalmology, found myopia progression reduced by 67 percent on average against single vision lenses, and by 71 percent, with 53 percent less axial elongation, in children who wore them full time, meaning twelve or more hours a day. Follow up data out to five and six years reports progression slowed by roughly 1.75 to 1.95 diopters versus projected controls, and a switching study found no rebound when wearers moved back to ordinary lenses for six months.

Two caveats belong next to those numbers, and they come from the study designs themselves, not from this site. First, the effect is strongly wear time dependent: children under twelve hours a day got meaningfully less benefit. Second, the five and six year figures compare against an extrapolated control group rather than a live one, because the original controls were switched onto the treatment lens after two years. That is normal trial ethics and it is also a softer standard of evidence than the first two years.

What do Stellest lenses cost?

Retailer listed prices, lenses only, before frames: around 360 pounds in the UK, around 600 Australian dollars, and about 375 Canadian dollars a pair at clinics that publish a figure. US pricing is not published and varies by retailer. Adaptation complaints in the first week, mild headache and eye tiredness, are commonly reported by fitting practices and usually resolve; anything persisting past two weeks is treated as a refit question.

How does Stellest compare to MiSight and MiyoSmart?

MiSight, CooperVision’s daily contact lens, reported 59 percent less progression and 52 percent less axial elongation over its three year trial. MiyoSmart, Hoya’s spectacle lens using the DIMS design, reported 52 and 62 percent over two years. Stellest’s two year figures sit at 67 and 53. These trials ran in different populations over different durations, so treating the percentages as a leaderboard is exactly the kind of reading the researchers themselves warn against. The honest summary is that all three produce a real, similar sized slowing effect in children, and none of them is dramatically ahead of the others on evidence that allows a direct comparison.

What do the percentages actually mean?

This is the part the marketing consistently leaves out. A 67 percent reduction in progression means a child who would have gained 1.00 diopter of myopia gains about 0.33 instead. The myopia still increases. No trial of Stellest, or of any competing lens, reports eyes getting less myopic. The product category is called myopia control, not myopia reversal, and the label is accurate.

It is also, on the published evidence, a childhood intervention. The trials enrolled children aged 8 to 13, the FDA authorization covers 6 to 12, and there is no adult efficacy data anywhere in the literature. An adult asking whether these lenses will help their own eyes is asking a question the evidence does not answer.

Why these lenses matter beyond children’s glasses

Here is the interesting part that neither the lens industry nor its critics dwell on. For decades the standard position was that lenses simply correct blur and have no effect on how the eye grows. Stellest, MiSight and MiyoSmart are all built on the opposite premise: that the optical signal reaching the retina steers axial growth, and that changing the signal changes the growth. That mechanism is now the basis of FDA authorized products. What remains genuinely untested is whether the same adaptation can run the other way in adults. Conventional optometry says no. A longer page on this site lays out that argument, and the case registry documents 363 adult self reports, 61 of them with third party verification (dataset DOI 10.5281/zenodo.21016339), as an open question rather than proof, stated with the registry’s own limits: self reported, subject to selection and survivorship bias, not a controlled trial.

https://join.endmyopia.org/?source=stellest

However you land on that, the practical advice in every direction is the same one this site gives about its own claims: trust nobody’s marketing, including ours. Measure. A child on any myopia control lens should have axial length or refraction tracked over time, because that number, not the brochure percentage, is the only thing that says whether it is working for that particular pair of eyes.

Common questions

Are Stellest lenses FDA approved?

FDA market authorized, September 2025, for slowing myopia progression in children aged 6 to 12 who wear them full time. Market authorization is a lighter pathway than full approval, and it was the first granted to any spectacle lens for this purpose.

Can adults wear Stellest lenses?

Nothing stops an adult from wearing them as ordinary correction, but every efficacy trial enrolled children, and no published data shows any myopia control effect in adults. The honest answer is that nobody has tested it.

Do Stellest lenses reverse myopia?

No, and Essilor does not claim they do. The trials show slower progression, not improvement. The documented cases of adult myopia reduction collected on this site come from a different approach entirely and remain, by this site’s own description, an open question rather than settled science.